These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000]. Melo-Cristino J; Fernandes ML; Serrano N; Acta Med Port; 2001; 14(5-6):459-68. PubMed ID: 11878155 [TBL] [Abstract][Full Text] [Related]
8. [Rational antibiotic therapy of acute upper respiratory tract infections]. Mazur E Pol Merkur Lekarski; 2010 Nov; 29(173):304-8. PubMed ID: 21268914 [TBL] [Abstract][Full Text] [Related]
9. Cefpodoxime proxetil suspension compared with cefaclor suspension for treatment of acute otitis media in paediatric patients. MacLoughlin GJ; Barreto DG; de la Torre C; Pinetta EA; del Castillo F; Palma L J Antimicrob Chemother; 1996 Mar; 37(3):565-73. PubMed ID: 9182113 [TBL] [Abstract][Full Text] [Related]
10. Antibiotic resistance. Epidemiology of resistance--respiratory tract infections. Thomson CJ J Med Microbiol; 1997 Jun; 46(6):442-5. PubMed ID: 9379469 [No Abstract] [Full Text] [Related]
11. Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens. Owens RC; Tessier P; Nightingale CH; Ambrose PG; Quintiliani R; Nicolau DP Int J Antimicrob Agents; 2001 Jun; 17(6):483-9. PubMed ID: 11397619 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial resistance in respiratory tract pathogens: results of an international surveillance study. Thornsberry C; Sahm DF Chemotherapy; 2000; 46 Suppl 1():15-23. PubMed ID: 10810209 [TBL] [Abstract][Full Text] [Related]
14. Antibiotic sensitivity of Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes and Branhamella catarrhalis isolated from upper respiratory tract infections in Sweden. Kallings I; Bengtsson S; Christensen P; Holm SE; Lind L; Kalin M Scand J Infect Dis Suppl; 1983; 39():100-5. PubMed ID: 6359377 [TBL] [Abstract][Full Text] [Related]
15. Only the pneumococcus.. Olson LC; Jackson MA Pediatr Infect Dis J; 1999 Oct; 18(10):849-50. PubMed ID: 10530577 [No Abstract] [Full Text] [Related]
16. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents. Blondeau JM; Vaughan D; Laskowski R; Borsos S; Int J Antimicrob Agents; 2001 Jun; 17(6):457-64. PubMed ID: 11397615 [TBL] [Abstract][Full Text] [Related]
17. A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections. Bantar C; Nicola F; Fernandez Canigia L; Arenoso HJ; Soutric J; Montoto M; Blanco M; Smayevsky J; Jasovich A J Chemother; 2000 Jun; 12(3):223-7. PubMed ID: 10877517 [TBL] [Abstract][Full Text] [Related]
19. [Amoxicillin/clavulanic acid (875/125 mg). New pharmacodynamic aspects]. Lode H Dtsch Med Wochenschr; 1999 Dec; 124(48):1459-61. PubMed ID: 10615328 [No Abstract] [Full Text] [Related]
20. [Clinical and bacteriological studies of ceftriaxone (CTRX) once daily administration in pediatric patients with respiratory tract infections]. Hasui M; Kobayashi Y; Harada Y; Ono A; Okazaki H; Kino M; Hara T Jpn J Antibiot; 2001 Oct; 54(10):532-40. PubMed ID: 11771335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]